Kingfa Science (KINGFA)
Fast GrowerFairStock Score: 40/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹5,870 |
| Market Cap | ₹7,954.66 Cr |
| P/E Ratio | 40.81 |
| ROCE | 30.55% |
| ROE | 17.41% |
| Dividend Yield | 0% |
| Profit Growth | 26.2% |
| Debt/Equity | 0.01 |
| Sales Growth | 23.2% |
| Promoter Holding | 67.02% |
| 52-Week Range | ₹3,649.9 — ₹6,339.6 |
| Sector | Industrial Products |
| Book Value | ₹1,032.6 |
Strengths
- Exceptional profitability with ROE of 25.74% and ROCE of 30.55%
- Almost debt-free balance sheet with debt/equity of 0.01
- Strong profit growth of 30.44% on sales growth of 11.15%
- High promoter holding of 67.02% aligning interests
- Piotroski F-Score of 7/9 indicates solid financial health
Concerns
- Expensive valuation at P/E of 35.52 and P/B of 10.21
- PEG of 1.71 suggests growth is already priced in
- Zero dividend yield means no cash return while waiting
- Profit growth outpacing sales growth by a wide margin may not be sustainable
AI Analysis
When I look at Kingfa Science, I first see a business with remarkable internal numbers: a 25.74% return on equity, a 30.55% return on capital employed, and a debt-to-equity ratio of just 0.01. That is a balance sheet I could sleep on. Promoter holding at 67.02% also tells me owners are fully aligned with minority shareholders, and a Piotroski score of 7 out of 9 supports the idea that the financial health is genuinely solid. The latest quarter adds to the picture: sales of ₹489 Cr and net profit of ₹45 Cr. Profit growth of 30.44% while sales are growing at only 11.15% means margins are doing the heavy lifting. That can be a sign of pricing power, but it can also reverse quickly if competition heats up or input costs turn unfriendly. Now the hard part: price. At ₹4,922.70, the market cap is ₹5,968 Cr, or 35.52 times trailing earnings and 10.21 times book value. The book value is only ₹482.14. With zero dividend, my entire return depends on the company compounding and the market rewarding that growth. The PEG ratio of 1.71 tells me I am not buying growth at a discount. The FairStock score of 39/100 is mixed, and I think that is fair. This is a high-quality, fast-growing enterprise, but Graham's margin of safety is thin when you pay such a high multiple. A wonderful business can still be a poor investment at the wrong price. I would wait for a better price or a clearer runway of sustained growth before putting new money to work.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer